We treated isogenic HAP1-KO MBD4 and HAP1-WT cell lines with camptothecin, doxorubicin, gemcitabine, cytarabine, paclitaxel, and dacarbazine, an alkylating agent commonly used to treat uveal melanoma patients (together with its active form, MTIC). The gene discussed is HAP1; the disease is uveal melanoma.